SRPT vs. NTRA
Compare and contrast key facts about Sarepta Therapeutics, Inc. (SRPT) and Natera, Inc. (NTRA).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: SRPT or NTRA.
Correlation
The correlation between SRPT and NTRA is 0.36, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
SRPT vs. NTRA - Performance Comparison
Loading data...
Key characteristics
SRPT:
-1.00
NTRA:
0.89
SRPT:
-1.76
NTRA:
1.55
SRPT:
0.73
NTRA:
1.19
SRPT:
-0.88
NTRA:
1.65
SRPT:
-1.96
NTRA:
4.48
SRPT:
36.01%
NTRA:
9.30%
SRPT:
70.54%
NTRA:
48.18%
SRPT:
-98.17%
NTRA:
-77.74%
SRPT:
-78.80%
NTRA:
-13.38%
Fundamentals
SRPT:
$3.81B
NTRA:
$20.82B
SRPT:
-$2.64
NTRA:
-$1.46
SRPT:
159.25
NTRA:
0.00
SRPT:
1.71
NTRA:
11.37
SRPT:
3.34
NTRA:
16.80
SRPT:
$2.23B
NTRA:
$1.83B
SRPT:
$1.81B
NTRA:
$1.13B
SRPT:
-$117.73M
NTRA:
-$170.27M
Returns By Period
In the year-to-date period, SRPT achieves a -68.83% return, which is significantly lower than NTRA's -3.15% return.
SRPT
-68.83%
-36.29%
-66.82%
-70.19%
-18.04%
-24.11%
3.56%
NTRA
-3.15%
3.20%
-8.33%
42.61%
60.13%
27.52%
N/A
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
SRPT vs. NTRA — Risk-Adjusted Performance Rank
SRPT
NTRA
SRPT vs. NTRA - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Sarepta Therapeutics, Inc. (SRPT) and Natera, Inc. (NTRA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
SRPT vs. NTRA - Dividend Comparison
Neither SRPT nor NTRA has paid dividends to shareholders.
Drawdowns
SRPT vs. NTRA - Drawdown Comparison
The maximum SRPT drawdown since its inception was -98.17%, which is greater than NTRA's maximum drawdown of -77.74%. Use the drawdown chart below to compare losses from any high point for SRPT and NTRA. For additional features, visit the drawdowns tool.
Loading data...
Volatility
SRPT vs. NTRA - Volatility Comparison
Sarepta Therapeutics, Inc. (SRPT) has a higher volatility of 39.88% compared to Natera, Inc. (NTRA) at 10.98%. This indicates that SRPT's price experiences larger fluctuations and is considered to be riskier than NTRA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
SRPT vs. NTRA - Financials Comparison
This section allows you to compare key financial metrics between Sarepta Therapeutics, Inc. and Natera, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
SRPT vs. NTRA - Profitability Comparison
SRPT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Sarepta Therapeutics, Inc. reported a gross profit of 607.29M and revenue of 744.86M. Therefore, the gross margin over that period was 81.5%.
NTRA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Natera, Inc. reported a gross profit of 317.22M and revenue of 501.83M. Therefore, the gross margin over that period was 63.2%.
SRPT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Sarepta Therapeutics, Inc. reported an operating income of -300.39M and revenue of 744.86M, resulting in an operating margin of -40.3%.
NTRA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Natera, Inc. reported an operating income of -79.18M and revenue of 501.83M, resulting in an operating margin of -15.8%.
SRPT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Sarepta Therapeutics, Inc. reported a net income of -447.51M and revenue of 744.86M, resulting in a net margin of -60.1%.
NTRA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Natera, Inc. reported a net income of -66.94M and revenue of 501.83M, resulting in a net margin of -13.3%.